The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - Checkmate Pharmaceuticals; Clinical Care Options; Finch Therapeutics; Gerson Lehrman Group; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
John George Knecht
Employment - Cardinal Health; CLS Health; Incyte
Leadership - Kindred Hospital Clear Lake
Stock and Other Ownership Interests - Becton Dickinson; Checkpoint Therapeutics; Fortress Biotech; Myovant Sciences; Reviva Pharmaceuticals
Honoraria - OMNI Health Media
Research Funding - Atossa Therapeutics; Cosmo Pharmaceuticals; EQRx; Phanes Therapeutics; Takeda; Xilio Therapeutics
Travel, Accommodations, Expenses - Cardinal Health
 
Andrae Lavon Vandross
Employment - Next Oncology; Texas Oncology
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); BiOneCure (Inst); Chugai Pharma (Inst); Deciphera (Inst); Exelixis (Inst); Immunomedics (Inst); IMPAC Medical Systems (Inst); Kirilys Therapeutics (Inst); Kura Oncology (Inst); Lyvgen Biopharma (Inst); Medikine (Inst); Nanjing (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); OncoResponse (Inst); PMV Pharma (Inst); Sirnaomics (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Xilio Therapeutics (Inst); Yufan Biotechnologies (Inst); ZielBio (Inst)
 
Cesar Augusto Perez
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); Ayala Pharmaceuticals (Inst); Elpiscience (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
David Michael Miller
Stock and Other Ownership Interests - Checkpoint Therapeutics
Consulting or Advisory Role - Castle Biosciences; Checkpoint Therapeutics; Merck Sharp & Dohme; Pfizer/EMD Serono; Regeneron; Sanofi/Regeneron
Research Funding - Incyte
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pfizer; Regeneron; Sanofi/Aventis
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Apros Therapeutics; Arcus Biosciences; Ascendis Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals; Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; I-Mab (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); Molecular Templates (Inst); MT Group (Inst); NextCure (Inst); Nuvation Bio (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Alberto Bessudo
No Relationships to Disclose
 
Ekta Patel
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - MustangBio; Xilio Therapeutics
Patents, Royalties, Other Intellectual Property - MustangBio; TCR2 Therapeutics
 
Damiano Fantini
Employment - Lilly; Merck (I); Xilio Therapeutics
Stock and Other Ownership Interests - Lilly; Merck (I); Xilio Therapeutics
 
Sattanathan Paramasivan
Employment - Selecta Biosciences; Xilio Therapeutics
Stock and Other Ownership Interests - ADMA Biologics; Allogene Therapeutics; Allogene Therapeutics; Amylyx; AstraZeneca; Aurinia Pharmaceuticals; Biomarin; BridgeBio Pharma; Bristol Myers Squibb Foundation; Deciphera; Dicerna; Merck; Ocugen; Pfizer; Selecta Biosciences; Xilio Therapeutics
 
David Crowe
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Meghan Duncan
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Susan Uptain
Employment - Takeda (I); Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Katarina Luptakova
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)